TROPISETRON FOR POSTOPERATIVE NAUSEA AND VOMITING IN PATIENTS AFTER GYNAECOLOGICAL SURGERY

• Published in: British Journal of Anaesthesia Vol. 71; no. 5; pp. 677 - 680
• Main Authors: ZOMERS, P.J.W., LANGENBERG, C.J.M., BRUIJN, K. M. DE
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Oxford Elsevier Ltd 01.11.1993; Oxford University Press
• Subjects: Adult; Aged; Biological and medical sciences; Digestive system; Double-Blind Method; Female; Genital Diseases, Female - surgery; Humans; Indoles - therapeutic use; Medical sciences; Middle Aged; Nausea - prevention & control; Pharmacology. Drug treatments; Postoperative Complications - prevention & control; Serotonin Antagonists - therapeutic use; Tropisetron; Vomiting - prevention & control; Vomiting: nausea. tropisetron; Vomiting: nausea. tropisetron; Human; Postoperative; Intravenous administration; Gynecology; Nausea; Prevention; Chemotherapy; Treatment; Vomiting; S3 receptor; Digestive diseases; Female; Antagonist; Antiemetic
• ISSN: 0007-0912; 1471-6771
• DOI: 10.1093/bja/71.5.677

In a double-blind study, we have compared the prophylactic antiemetic effect of tropisetron 5 mg (Navoban, a 5-HT3 receptor antagonist) with that of placebo, both given as a short i.v. infusion approximately 15 min before wound closure in patients undergoing gynaecological surgery. Perioperative anaesthetic care was standardized and patients were observed for at least 24 h after operation, The 35 patients given tropisetron and 34 given placebo treatment were well matched for characteristics. Vomiting occurred in 26% of tropisetron-treated patients, compared with 59% of placebo-treated patients (P = 0.006); 69% of tropisetron-treated patients suffered nausea, compared with 88% of placebo-treated patients (P = 0.05). In addition, patients judged the antiemetic treatment with tropisetron as more effective than the placebo treatment (visual analogue score 71 vs 51mm (P = 0.003)). (Br. J. Anaesth. 1993; 71: 677–680)